(Reuters) -Spero Therapeutics and partner GSK said on Wednesday an experimental drug for complicated urinary tract infections met the main goal of a late-stage trial and the companies will be stopping the trial early for efficacy.
Spero shares nearly tripled to $2 in premarket trading.
The decision comes after a recommendation from an independent committee that completed a pre-specified interim analysis of data from 1,690 patients enrolled in the trial.
The companies were studying the oral drug, tebipenem HBr, as a treatment for complicated urinary tract infections, including pyelonephritis, in which kidneys become infected.
In the trial, the drug showed it was at least as good as an existing intravenous treatment in hospitalized adult patients.
GSK plans to work with U.S. regulatory authorities to include the data as part of a filing in the second half of the year.
(Reporting by Sriparna Roy in Bengaluru; Editing by Devika Syamnath)
Brought to you by www.srnnews.com
